Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart hormone boost may cut diabetes risk in black individuals — a trial puts it to the test

NCT ID NCT04055428

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

Black individuals often have lower levels of natriuretic peptides, heart hormones that help regulate metabolism. This trial tests whether raising those hormone levels with a drug called sacubitril/valsartan can improve insulin sensitivity and energy expenditure. About 200 Black adults with mildly elevated blood pressure but no heart disease will take either the study drug or a standard blood-pressure medication for 12 weeks. The goal is to see if boosting these hormones can lower the risk of diabetes in this population.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination drug (sacubitril/valsartan) that boosts natriuretic peptide levels
What this could lead to
If it works, this could point toward a way to lower diabetes risk in Black individuals by targeting a hormone pathway that is often underactive in this population.
What could go wrong
This is a mid-stage trial with 200 participants, so results may not apply broadly. The drug also lowers blood pressure, which could complicate interpretation of metabolic effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder diabetes mellitus Insulin Resistance metabolic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASES DIABETES MELLITUS ENERGY EXPENDITURE INSULIN SENSITIVITY/RESISTANCE METABOLIC DISEASE METABOLISM NATRIURETIC PEPTIDES

Contacts and locations

Locations

  • University of Alabama at Birmingham

    RECRUITING

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.